Q-omics provides the consensus-scored KRT28 profile across patient tissues and cancer cell-line models. KRT28 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT28 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, KRT28 RNA expression shows 4,955 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where KRT28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT28 survival associations across molecular data types. KRT28 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT28 RNA expression–survival associations across cancer types. High KRT28 expression shows unfavorable associations in KIRC, SKCM, SCLC, READ, KIRP and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT28 RNA expression.
This table summarizes KRT28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT28 shows lower tumor expression in COAD and LUSC and higher tumor expression in UCEC. The COAD box plot shows higher KRT28 RNA expression in normal versus tumor tissue (log2 FC = −0.008, t-test p = .019).
This table shows molecular features associated with KRT28 in patient tissues and cancer cell lines. In patient samples, KRT28 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
